The global burden of lung cancer: current status and future trends

被引:0
|
作者
Amanda Leiter
Rajwanth R. Veluswamy
Juan P. Wisnivesky
机构
[1] Icahn School of Medicine at Mount Sinai,Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine
[2] Icahn School of Medicine at Mount Sinai,Division of Hematology and Oncology, Department of Medicine
[3] Icahn School of Medicine at Mount Sinai,Division of General Internal Medicine, Department of Medicine
[4] Icahn School of Medicine at Mount Sinai,Tisch Cancer Institute
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer incidence and mortality rates differ substantially across the world, reflecting varying patterns of tobacco smoking, exposure to environmental risk factors and genetics. Tobacco smoking is the leading risk factor for lung cancer. Lung cancer incidence largely reflects trends in smoking patterns, which generally vary by sex and economic development. For this reason, tobacco control campaigns are a central part of global strategies designed to reduce lung cancer mortality. Environmental and occupational lung cancer risk factors, such as unprocessed biomass fuels, asbestos, arsenic and radon, can also contribute to lung cancer incidence in certain parts of the world. Over the past decade, large-cohort clinical studies have established that low-dose CT screening reduces lung cancer mortality, largely owing to increased diagnosis and treatment at earlier disease stages. These data have led to recommendations that individuals with a high risk of lung cancer undergo screening in several economically developed countries and increased implementation of screening worldwide. In this Review, we provide an overview of the global epidemiology of lung cancer. Lung cancer risk factors and global risk reduction efforts are also discussed. Finally, we summarize lung cancer screening policies and their implementation worldwide.
引用
收藏
页码:624 / 639
页数:15
相关论文
共 50 条
  • [11] Lung cancer chemoprevention: current status and future directions
    Jenny T. Mao
    Ravi Durvasula
    [J]. Current Respiratory Care Reports, 2012, 1 (1): : 9 - 20
  • [12] Lung cancer vaccines: current status and future prospects
    Ramlogan-Steel, Charmaine A.
    Steel, Jason C.
    Morris, John C.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (01) : 46 - 52
  • [13] Lung cancer chemoprevention: current status and future prospects
    Robert L. Keith
    York E. Miller
    [J]. Nature Reviews Clinical Oncology, 2013, 10 : 334 - 343
  • [14] Chemoprevention of lung cancer: current status and future prospects
    van Zandwijk, N
    Hirsch, FR
    [J]. LUNG CANCER, 2003, 42 : S71 - S79
  • [15] IMRT for lung cancer: current status and future developments
    Faivre-Finn, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S294 - S294
  • [16] Lung cancer chemoprevention: current status and future prospects
    Keith, Robert L.
    Miller, York E.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (06) : 334 - 343
  • [17] Chemoprevention of Lung Cancer: Current Status and Future Prospects
    Victor Cohen
    Fadlo R. Khuri
    [J]. Cancer and Metastasis Reviews, 2002, 21 : 349 - 362
  • [18] Current status and future perspectives of immunotherapy in lung cancer
    Yoshida, Tatsuya
    [J]. CANCER SCIENCE, 2023, 114 : 1765 - 1765
  • [19] Radon and lung cancer: Current status and future prospects
    Liu, Yan
    Xu, Yanqing
    Xu, Wei
    He, Zhengzhong
    Fu, Cong
    Du, Fen
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
  • [20] Chemoprevention of lung cancer: Current status and future prospects
    Cohen, V
    Khuri, FR
    [J]. CANCER AND METASTASIS REVIEWS, 2002, 21 (3-4) : 349 - 362